Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Merck's operating assets for the quarter that ended in Dec. 2023 was $99,582 Mil. Merck's operating liabilities for the quarter that ended in Dec. 2023 was $33,985 Mil. Merck's Total Assets for the quarter that ended in Sep. 2023 was $106,727 Mil. Therefore, Merck's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.61.
Merck Scaled Net Operating Assets Historical Data
The historical data trend for Merck's Scaled Net Operating Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Merck Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Scaled Net Operating Assets |
|
|
|
|
|
|
0.51 |
0.58 |
0.69 |
0.60 |
0.60 |
|
Merck Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Scaled Net Operating Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.59 |
0.62 |
0.64 |
0.65 |
0.62 |
Competitive Comparison
For the Drug Manufacturers - General subindustry, Merck's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merck Scaled Net Operating Assets Distribution
For the Drug Manufacturers industry and Healthcare sector, Merck's Scaled Net Operating Assets distribution charts can be found below:
* The bar in red indicates where Merck's Scaled Net Operating Assets falls into.
Merck Scaled Net Operating Assets Calculation
Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.
Merck's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (A: Dec. 2023 ) |
| = | (Operating Assets (A: Dec. 2023 ) | - | Operating Liabilities (A: Dec. 2023 )) | / | Total Assets (A: Dec. 2022 ) |
| = | (99582 | - | 33985) | / | 109160 |
| = | 0.60 |
where
Merck's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as
| Scaled Net Operating Assets (SNOA) | | (Q: Dec. 2023 ) |
| = | (Operating Assets (Q: Dec. 2023 ) | - | Operating Liabilities (Q: Dec. 2023 )) | / | Total Assets (Q: Sep. 2023 ) |
| = | (99582 | - | 33985) | / | 106727 |
| = | 0.61 |
where
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck (MRK) Business Description
Traded in Other Exchanges
Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.
Executives
| Johannes Jacobus Oosthuizen |
officer: SVP, U.S. Market |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Richard R. Deluca |
officer: EVP&Pres, Merck Animal Heallth |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Steven Mizell |
officer: EVP,Human Resources |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Joseph Romanelli |
officer: President, Human Health Int?l |
126 EAST LINCOLN AVENUE, RAHWAY NJ 07065 |
| Rita A Karachun |
officer: Sr. VP Fince-Global Controller |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Jennifer Zachary |
officer: EVP, General Counsel |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| David Michael Williams |
officer: EVP,Chief Info&Digital Officer |
MERCK & CO., INC., 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Robert M Davis |
officer: Evp, Global Svcs & CFO |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Sanat Chattopadhyay |
officer: Exe V-P & Pres. MMD |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Kenneth C Frazier |
officer: Chairman, President & CEO |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
| Chirfi Guindo |
officer: Chief Marketing Officer |
C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142 |
| Baker Douglas M Jr |
director |
370 WBASHA ST NORTH, ST PAUL MN 55102 |
| Arpa Garay |
officer: SVP Human Health Global Mktg. |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Caroline Litchfield |
officer: EVP & CFO |
2000 GALLOPING HILL RD, KENILWORTH NJ 07033 |
| Julie L. Gerberding |
officer: EVP Strat Comm, GI Pub Policy |
2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRK has been successfully added to your